Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for September 5, 2024, at 4:05 p.m. ET in New York.

Management will engage in a fireside chat during the conference. Investors and interested parties can access a live webcast of the presentation through Dyne's website in the Investors & Media section. The replay will remain available for 90 days after the event.

This participation highlights Dyne's commitment to advancing innovative therapeutics for individuals with genetically driven muscle diseases and provides an opportunity for the company to share insights with the healthcare investment community.

News Market Reaction – DYN

+0.56%

+0.56% Session move

In the trading session that priced this news, DYN gained 0.56%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 22^nd Annual Global Healthcare Conference being held in New York on Thursday, September 5, 2024 at 4:05 p.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contact:

Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

When is Dyne Therapeutics (DYN) presenting at the Morgan Stanley Healthcare Conference?

Dyne Therapeutics (DYN) is scheduled to present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 4:05 p.m. ET in New York.

How can I watch Dyne Therapeutics' (DYN) presentation at the Morgan Stanley conference?

A live webcast of Dyne Therapeutics' (DYN) presentation will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations.

How long will the replay of Dyne Therapeutics' (DYN) Morgan Stanley conference presentation be available?

The replay of Dyne Therapeutics' (DYN) presentation at the Morgan Stanley conference will be accessible for 90 days following the event.

What is the focus of Dyne Therapeutics (DYN) as a company?

Dyne Therapeutics (DYN) is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.